Survival follow up of JO25567, a randomized phase 2 study comparing erlotinib and bevacizumab combination with erlotinib alone in NSCLC patients harboring EGFR mutation. First published 07/08/2018 Last updated 14/03/2024 EU PAS number:EUPAS25131 Study Finalised